ArticleCancer management and research2025
Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of neoadjuvant therapy and identify associated factors influencing treatment response in patients with HER2-positive breast cancer. Subjects and Methods: A prospective, longitudinal study of 40 women with a mean age of 50.68 ± 10.53 years diagnosed with HER2-positive breast cancer. All patients received neoadjuvant treatment using Docetaxel-Carboplatin-Trastuzumab (TCH) regimens. These patients were evaluated for treatment response based on the Response Evaluation Criteria In Solid Tumors (RECIST) after six 21-day treatment cycles. Results: The proportion of good responders was 45.0% (18/40 patients). Younger age, earlier clinical stage, and lower baseline serum CA15-3 levels were significantly associated with a better response (p < 0.05). The incidence of adverse events was also significantly lower in good responders (p < 0.05). Multivariate analysis identified younger age and lower CA15-3 concentration as independent predictors of favorable response, with area under the Receiver Operating Characteristic (ROC) curves (AUC) of 0.758 and 0.821, respectively (p = 0.006 and p = 0.001). Conclusion: Neoadjuvant treatment using the Docetaxel-Carboplatin-Trastuzumab regimen provides favorable clinical outcomes in HER2-positive breast cancer patients. Baseline CA15-3 levels may serve as a useful predictor of treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.